Maryland Heights, MO, March 04, 2017 --(PR.com
)-- The global hospital pharmaceutical drugs market is estimated to reach USD 235 Billion in 2020, expanding at a CAGR of 2.8% from 2016 to 2020, due to rising healthcare expenditure and prevalence of chronic diseases worldwide.
Browse Hospital Pharmaceutical Drugs Market by Indication (Coronary Heart Diseases, Heart Failure, High Blood Pressure, Stroke, Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Acute Kidney Failure, Chronic Kidney Diseases, Diabetes, Glomerular Diseases, Alzheimer’s Disease, Epilepsy, Multiple Sclerosis, Parkinson’s Disease, Cancer Pain, Fibromyalgia, Neuropathic Pain, Osteoarthritis, Rheumatoid Arthritis, Amoebiasis, Candida Infection, Tuberculosis, Fungal Meningitis, Hepatitis A, Hepatitis B, Pneumonia, Shigellosis), Therapeutics (Anti-Adrenergic Drugs, Anti-Arrhythmic Drugs, Calcium Channel Blockers, Diuretic Drugs, 5-Alpha Reductase Inhibitors, Alkylating Agents, Anticholinergic Drugs, Anti-Hypertensive Agents, Anti-Metabolites, Diuretic Agents, Hormonal Agents, Immunomodulation Agents, Miscellaneous Drugs, Phosphate Binders, Neurology, Anti-Anxiety Agents, Antidepressant Drugs, Anti-Migraine Drugs, Anti-Psychotic Drugs, Anesthetic Drugs, Anticonvulsant Drugs, Non-Narcotics Analgesic Drugs, Non-Steroidal Anti-Inflammatory Drugs, Opioids, Antibacterial Drugs, Antifungal Drugs, Anti-parasite Drugs, and Antiviral Drugs) and Therapeutic Application (Cardiology, Oncology, Nephrology and Urology, Pain and Infection Categories) 2016-2020 at https://www.ihealthcareanalyst.com/report/hospital-pharmaceuticals-market/.
Hospital pharmaceuticals are medications and drugs administered to patients in hospital settings that include both in-patient and out-patient treatment. Increasing prevalence of diseases, affordability, rising awareness, and healthcare spending are some of the factors driving the hospital pharmaceuticals market growth in emerging economies of Asia Pacific and Rest of the World.
The global hospital pharmaceutical drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the indications (coronary heart diseases, heart failure, high blood pressure, stroke, breast cancer, colorectal cancer, lung cancer, prostate cancer, acute kidney failure, chronic kidney diseases, diabetes, glomerular diseases, Alzheimer’s disease, epilepsy, multiple sclerosis, Parkinson’s disease, cancer pain, fibromyalgia, neuropathic pain, osteoarthritis, rheumatoid arthritis, amoebiasis, candida infection, tuberculosis, fungal meningitis, hepatitis A, hepatitis B, pneumonia, shigellosis; while therapeutics include anti-adrenergic drugs, anti-arrhythmic drugs, calcium channel blockers, diuretic drugs, 5-alpha reductase inhibitors, alkylating agents, anticholinergic drugs, anti-hypertensive agents, anti-metabolites, diuretic agents, hormonal agents, immunomodulation agents, miscellaneous drugs, phosphate binders, neurology, anti-anxiety agents, antidepressant drugs, anti-migraine drugs, anti-psychotic drugs, anesthetic drugs, anticonvulsant drugs, non-narcotics analgesic drugs, non-steroidal anti-inflammatory drugs, opioids, antibacterial drugs, antifungal drugs, antiparasite drugs, and antiviral drugs) and therapeutic applications in cardiology, oncology, nephrology and urology, pain and infection categories, and forecasts growth trends (CAGR% - 2016 to 2020).
The global hospital pharmaceutical drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global hospital pharmaceutical drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global hospital pharmaceutical drugs market and included in this report are AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Novartis, and Pfizer, Inc.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/hospital-pharmaceuticals-market/
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive
Maryland Heights, MO 63043